On August 17, 2026, Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) completed an underwritten public offering of its common stock, selling 26,450,000 shares, with an additional 3,450,000 shares sold through the underwriters' option exercise. Priced at $3.50 per share, the total gross proceeds amounted to around $92.6 million before deductions for underwriting discounts, commissions, and offering expenses. The Company solely sold all the shares in this public offering, advancing its late-stage development of the WEE1 inhibitor, azenosertib, for ovarian cancer treatment with a biomarker-driven approach.